Weaknesses in the UN drug control system have often been identified, related to the functioning of the key organs UNODC, INCB, and the CND; related to collaboration with the wider UN system (WHO, UNAIDS, UNDP, etc.) and related to the outdated character of several treaty provisions. What has been attempted to date to achieve more structural reform? Are existing evaluation mechanisms capable of bringing the need for reform to the table? How could a neutral and evidence-based role of UNODC as a centre of expertise be strengthened? How can these issues be related to the UN call for more ‘system-wide coherence’ and ‘delivery as one’?

Page 2 of 5